MatchMiner: an open-source platform for cancer precision medicine.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
06 Oct 2022
06 Oct 2022
Historique:
received:
10
01
2022
accepted:
15
09
2022
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
7
10
2022
Statut:
epublish
Résumé
Widespread, comprehensive sequencing of patient tumors has facilitated the usage of precision medicine (PM) drugs to target specific genomic alterations. Therapeutic clinical trials are necessary to test new PM drugs to advance precision medicine, however, the abundance of patient sequencing data coupled with complex clinical trial eligibility has made it challenging to match patients to PM trials. To facilitate enrollment onto PM trials, we developed MatchMiner, an open-source platform to computationally match genomically profiled cancer patients to PM trials. Here, we describe MatchMiner's capabilities, outline its deployment at Dana-Farber Cancer Institute (DFCI), and characterize its impact on PM trial enrollment. MatchMiner's primary goals are to facilitate PM trial options for all patients and accelerate trial enrollment onto PM trials. MatchMiner can help clinicians find trial options for an individual patient or provide trial teams with candidate patients matching their trial's eligibility criteria. From March 2016 through March 2021, we curated 354 PM trials containing a broad range of genomic and clinical eligibility criteria and MatchMiner facilitated 166 trial consents (MatchMiner consents, MMC) for 159 patients. To quantify MatchMiner's impact on trial consent, we measured time from genomic sequencing report date to trial consent date for the 166 MMC compared to trial consents not facilitated by MatchMiner (non-MMC). We found MMC consented to trials 55 days (22%) earlier than non-MMC. MatchMiner has enabled our clinicians to match patients to PM trials and accelerated the trial enrollment process.
Identifiants
pubmed: 36202909
doi: 10.1038/s41698-022-00312-5
pii: 10.1038/s41698-022-00312-5
pmc: PMC9537311
doi:
Types de publication
Journal Article
Langues
eng
Pagination
69Informations de copyright
© 2022. The Author(s).
Références
Adv Exp Med Biol. 2016;890:v-vi
pubmed: 27119128
Lancet Oncol. 2019 Mar;20(3):e175-e186
pubmed: 30842061
Nat Med. 2017 Jun;23(6):703-713
pubmed: 28481359
Oncologist. 2017 Feb;22(2):144-151
pubmed: 28179575
Ther Adv Med Oncol. 2019 Jun 18;11:1758835919856494
pubmed: 31244912
JCO Clin Cancer Inform. 2020 Jul;4:602-613
pubmed: 32644817
JCO Precis Oncol. 2017;2017:
pubmed: 30003184
Int J Mol Sci. 2021 Mar 05;22(5):
pubmed: 33807876
J Clin Oncol. 2014 May 1;32(13):1317-23
pubmed: 24663044
Clin Cancer Res. 2014 Sep 1;20(17):4425-35
pubmed: 25183480
Arch Pathol Lab Med. 2017 Jun;141(6):751-758
pubmed: 28557599
JAMIA Open. 2019 Oct 07;2(4):505-515
pubmed: 32025647
Nat Commun. 2020 Oct 2;11(1):4965
pubmed: 33009371
Mol Oncol. 2019 Mar;13(3):549-557
pubmed: 30698321
J Clin Oncol. 2013 May 20;31(15):1849-57
pubmed: 23589548
J Clin Oncol. 2015 Mar 20;33(9):975-7
pubmed: 25667288
Cancers (Basel). 2019 Aug 16;11(8):
pubmed: 31426419
Oncology (Williston Park). 2020 Oct 9;34(10):407-412
pubmed: 33058107
J Clin Oncol. 2001 Mar 15;19(6):1728-33
pubmed: 11251003
J Am Med Inform Assoc. 2016 Jul;23(4):777-81
pubmed: 27016727
BMJ Open. 2017 Oct 11;7(10):e017719
pubmed: 29025842
JCO Clin Cancer Inform. 2021 Feb;5:221-230
pubmed: 33625877
Am Soc Clin Oncol Educ Book. 2018 May 23;38:546-553
pubmed: 30231369
J Am Med Inform Assoc. 2016 Jul;23(4):701-10
pubmed: 27018265
J Natl Cancer Inst. 2015 Jul 03;107(7):
pubmed: 26142446
Am Soc Clin Oncol Educ Book. 2018 May 23;38:188-196
pubmed: 30231363
Clin Cancer Res. 2012 Nov 15;18(22):6373-83
pubmed: 22966018
J Clin Oncol. 2015 Mar 20;33(9):1000-7
pubmed: 25667274
JCO Clin Cancer Inform. 2019 Jul;3:1-11
pubmed: 31265323
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
J Clin Oncol. 2015 Sep 1;33(25):2753-62
pubmed: 26014291
J Mol Diagn. 2016 Jul;18(4):507-15
pubmed: 27339098
JCI Insight. 2016 Nov 17;1(19):e87062
pubmed: 27882345
J Am Med Inform Assoc. 2015 Nov;22(6):1173-8
pubmed: 26198304
Am Soc Clin Oncol Educ Book. 2018 May 23;38:708-715
pubmed: 30231309
Genome Med. 2016 Oct 25;8(1):109
pubmed: 27782854
J Oncol Pract. 2015 Nov;11(6):442-9
pubmed: 26243651
JCO Precis Oncol. 2021 Jul 09;5:
pubmed: 34632252
Cancer Treat Rev. 2015 May;41(5):385-90
pubmed: 25864024
NPJ Precis Oncol. 2017 Apr 24;1(1):12
pubmed: 29872700
Adv Exp Med Biol. 2016;893:155-178
pubmed: 26667343